Advanced search
Publication Cover
Expert Review of Vaccines Volume 7, 2008 - Issue 8
Submit an article Journal homepage
325
Views
31
CrossRef citations to date
0
Altmetric
Review

Smallpox vaccines for biodefense: need and feasibility

Andrew W Artensteina Department of Medicine, Director, Center for Biodefense and Emerging Pathogens and Associate Professor of Medicine and Community Health, Alpert Medical School of Brown University and Department of Medicine, Memorial Hospital of RI, 111 Brewster Street, Pawtucket, RI 02860, USA. [email protected]
&
John D Grabensteinb Adult Vaccine Medical Affairs, Merck Vaccines and Infectious Diseases, 770 Sumneytown Pike, WP97-A279, West Point, PA 19486, USA. [email protected]
Pages 1225-1237 | Published online: 09 Jan 2014

References

  • Center for Disease Control and Prevention. Achievements in public health, 1900–1999 impact of vaccines universally recommended for children – United States, 1990–1998. MMWR Morb. Mortal. Wkly Rep.48(12), 243–248 (1999).
  • Barquet N, Domingo P. Smallpox: the triumph over the most terrible of the ministers of death. Ann. Intern. Med.127(8), 635–642 (1997).
  • Fenner F, Henderson DA, Arita I, Zdenêk J, Ladnyi ID. Smallpox and its Eradication. World Health Organization, Geneva, Switzerland (1988).
  • Stern A, Markel H. The history of vaccines and immunization: familiar patterns, new challenges. Health Aff.24(3), 611–621 (2005).
  • Parish HJ. A History of Immunization. E & S Livingstone Ltd, Edinburgh, UK (1965).
  • Artenstein AW, Opal JM, Opal SM et al. History of US military contributions to the study of vaccines against infectious diseases. Mil. Med.170(4), 3–11 (2005).
  • Hammarsten JF, Tattersall W, Hammarsten JE. Who discovered smallpox vaccination? Edward Jenner or Benjamin Jesty? Trans. Am. Clin. Climatol. Assoc.90, 44–55 (1979).
  • Riedel S. Edward Jenner and the history of smallpox and vaccination. Proc. (Bayl. Univ. Med. Cen.)18, 21–25 (2005).
  • Baxby D. Edward Jenner’s inquiry; a bicentenary ana­lysis. Vaccine17, 301–307 (1999).
  • Grabenstein JD, Pittman PR, Greenwood JT, Engler RJM. Immunization to protect the US armed forces: heritage, current practice, and prospects. Epidemiol. Rev.28, 3–26 (2006).
  • Wade N. New smallpox case seems lab-caused. Science201(4359), 893 (1978).
  • Redfield RR, Wright DC, James WD et al. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N. Engl. J. Med.316, 673–676 (1987).
  • Moloo H, Artenstein AW. History of vaccines. In: Encyclopedia of Public Health. Murray CJ (Ed.). Elsevier (2008).
  • Henderson DA, Inglesby TV, Bartlett JG et al. Smallpox as a biological weapon. JAMA281, 2127–2137 (1999).
  • Breman JG, Henderson DA. Diagnosis and management of smallpox. N. Engl. J. Med.346, 1300–1308 (2002).
  • Ennis FA, Cruz J, Demkowicz Jr WE et al. Primary induction of human CD8 cytotoxic T lymphocytes and interferon-γ- producing T cells after smallpox vaccination. J. Infect. Dis.185, 1657–1659 (2002).
  • Artenstein AW. New generation smallpox vaccines: a review of preclinical and clinical data. Rev. Med. Virol.18(4), 217–231 (2008).
  • Frey SE, Newman FK, Yan L et al. Response to smallpox vaccine in persons immunized in the distant past. JAMA289, 3295–3299 (2003).
  • Murphy FA, Osburn BI. Adventitious agents and smallpox vaccine in strategic national stockpile. Emerg. Infect. Dis.11(7), 1086–1089 (2005).
  • Weltzin R, Liu J, Pugachev KV et al. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat. Med.9, 1125–1130 (2003).
  • Monath TP, Caldwell JR, Mundt W et al. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) – a second-generation smallpox vaccine for biological defense. Int. J. Infect. Dis.8(S2), S31–S44 (2004).
  • Artenstein AW, Johnson C, Marbury TC et al. A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine23, 3301–3309 (2005).
  • Acambis, Inc. Investigator’s brochure for ACAM2000 smallpox vaccine. Acambis, Inc, MA, USA (2002).
  • Greenberg RN, Kennedy JS, Clanton DJ et al. Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomized controlled trial. Lancet365, 389–409 (2005).
  • Hashizume S; Chiba Serum Institute. Special edition future of vaccination: everything about attenuated vaccines. Basics of new attenuated vaccine strain LC16m8. Clin. Virus3, 229–235 (1975).
  • Hashizume S, Yoshizawa N, Morita M Suzuki K. Properties of attenuated mutant of vaccinia virus, LC16m8, derived from Lister strain. In: Vaccinia Viruses as Vectors for Vaccine Antigens. Quinnan GV (Ed.). Elsevier, NY, USA (1985).
  • Kenner J, Cameron F, Empig C et al. LC16m8: an attenuated smallpox vaccine. Vaccine24, 7009–7022 (2006).
  • Wiser I, Balicer RD, Cohen D. An update on smallpox vaccine candidates and their role in bioterrorism related vaccination strategies. Vaccine25, 976–984 (2007).
  • Empig C, Kenner JR, Perret-Gentil M et al. Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge. Vaccine24, 3686–3694 (2006).
  • Kidokoro M, Tashiro M, Shida H. Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8. Proc. Natl Acad. Sci. USA102, 1452–1457 (2005).
  • Yokote H, Shinmura Y, Satou A et al. Safety and efficacy study of attenuated smallpox vaccine LC16m8 in animals. Presented at: 2006 ASM Biodefense Research Meeting for the American Society for Microbiology. Washington, DC, USA, 15–18 February 2006.
  • Fujii T, Kannatani Y, Matsumura T et al. Clinical evaluation of attenuated smallpox vaccine LC16m8 in Japan. Presented at: 2006 ASM Biodefense Research Meeting for the American Society for Microbiology. Washington, DC, USA, 15–18 February 2006.
  • Kenner JR, Gurwith M, Luck A et al. Safety and immunogenicity of attenuated smallpox vaccine, LC16m8: results from a Phase 2 study. Presented at: 2006 ASM Biodefense Research Meeting for the American Society for Microbiology. Washington, DC, USA, 15–18 February 2006.
  • Mayr A, Stickl H, Müller HK et al. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defense mechanism (author’s transl). Zentralbl. Bakteriol. [B].167, 375–390 (1978).
  • McCurdy LH, Larkin BD, Martin JE et al. Modified vaccinia Ankara: potential as an alternative smallpox vaccine. Clin. Infect. Dis.38, 1749–1753 (2004).
  • Parrino J, Graham BS. Smallpox vaccines: past, present, and future. J. Allergy Clin. Immunol.118, 1320–1326 (2006).
  • Stittelaar KJ, Kuiken T, de Swart RL et al. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine19, 3700–3709 (2001).
  • Wyatt LS, Earl PL, Eller LA et al. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc. Natl Acad. Sci. USA101, 4590–4595 (2004).
  • Meseda CA, Garcia AD, Jumar A et al. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology339, 164–175 (2005).
  • Earl PL, Americo JL, Wyatt LS et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature428, 182–185 (2004).
  • Stettelaar KJ, van Amerongen G, Kondova I et al. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J. Virol.79, 7845–7851 (2005).
  • McCurdy LH, Rutigliano JA, Johnson TR et al. Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4. J. Virol.78, 12471–12479 (2004).
  • Abdalrhman I, Gurt I, Katz E. Protection induced in mice against a lethal orthopox virus by the Lister strain of vaccinia virus and modified vaccinia virus Ankara (MVA). Vaccine24, 4152–4160 (2006).
  • Vollmar J, Arndtz N, Eckl KM et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine24, 2065–2070 (2006).
  • Parrino J, McCurdy LH, Larkin BD et al. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax® challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine25, 1513–1525 (2007).
  • Tartaglia J, Perkus ME, Taylor J et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology188(1), 217–232, (1992).
  • Nájera JL, Gómez CE, Domingo-Gil E et al. Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J. Virol.80, 6033–6047 (2006).
  • Edghill-Smith Y, Venzon D, Karpova T et al. Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques. J. Infect. Dis.188, 1181–1191 (2003).
  • Edghill-Smith Y, Bray M, Whitehouse CA et al. Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge. J. Infect. Dis.191, 372–381 (2005).
  • Ober BT, Brűhl P, Schmidt M et al. Immunogenicity and safety of defective vaccinia virus Lister: comparison with modified vaccinia virus Ankara. J. Virol.76, 7713–7723 (2002).
  • Coulibaly S, Brűhl P, Mayrhofer J et al. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology341, 91–101 (2005).
  • Davies DH, McCausland MM, Valdez C et al. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J. Virol.79, 11724–11733 (2005).
  • Fogg C, Lustig S, Whitbeck C et al. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J. Virol.78, 10230–10237 (2004).
  • Hooper JW, Thompson E, Wilhelmsen C et al. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J. Virol.78, 1133–1143 (2004).
  • Pulford DJ, Gates A, Bridge SH et al. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunization in protection of BALB/c mice from a lethal intranasal poxvirus challenge. Vaccine22, 3358–3366 (2004).
  • Lane JM, Ruben RL, Neff JM et al. Complications of smallpox vaccination, 1968: national surveillance in the United States. N. Engl. J. Med.281, 1201–1208 (1969).
  • Lane JM, Ruben FL, Neff JM et al. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J. Infect. Dis.122, 303–309 (1970).
  • Fulginiti VA, Papier A, Lane JM et al. Smallpox vaccination: a review, Part II. Adverse events. Clin. Infect. Dis.37, 251–271 (2003).
  • Kretzschmar M, Wallinga J, Teunis P et al. Frequency of adverse events after vaccination with different vaccinia strains. PLoS Med.3, 1341–1351 (2006).
  • Lane JM, Millar JD. Risks of smallpox vaccination complications in the United States. Am. J. Epidemiol.93, 238–240 (1971).
  • Miravalle A, Roos KL. Encephalitis complicating smallpox vaccination. Arch. Neurol.60, 925–928 (2003).
  • Strikas RA, Neff LJ, Rotz L et al. US civilian smallpox preparedness and response program, 2003. Clin. Infect. Dis.46(Suppl. 3), 157–167 (2008).
  • Center for Disease Control and Prevention. Surveillance guidelines for smallpox vaccine (vaccinia) adverse reactions. MMWR Morb. Mortal. Wkly Rep.55(RR01), 1–16 (2006).
  • Neff JM, Lane JM, Fulginiti VA et al. Contact vaccinia-transmission of vaccinia from smallpox vaccination. JAMA288, 1901–1905 (2002).
  • Kemper AR, Davis MM, Freed GL. Expected adverse events in a mass smallpox vaccination campaign. Eff. Clin. Pract.5, 84–90 (2002).
  • Lane MJ, Goldstein J. Evaluation of 21st Century risks of smallpox vaccination and policy options. Ann. Intern. Med.138, 488–493 (2003).
  • Auckland C, Cowlishaw A, Morgan D et al. Reactions to smallpox vaccine in naive and previously-vaccinated individuals. Vaccine23, 4185–4187 (2003).
  • Baggs J, Chen RT, Damon IK et al. Safety profile of smallpox vaccine: insights from the laboratory worker smallpox vaccination program. Clin. Infect. Dis.40, 1133–1140 (2005).
  • Couch RB, Winokur P, Edwards KM et al. Reducing the dose of smallpox vaccine reduces vaccine-associated morbidity without reducing vaccination success rates or immune responses. J. Infect. Dis.195, 826–832 (2007).
  • Grabenstein JD, Winkenwerder W. US military smallpox vaccination program experience. JAMA289, 3278–3282 (2003).
  • Sejvar JJ, Labutta RJ, Chapman LE et al. Neurologic adverse events associated with smallpox vaccination in the United States, 2002–2004. JAMA294, 2744–2750 (2005).
  • Lewis FS, Norton SA, Bradshaw D et al. Analysis of cases reported as generalized vaccinia during the US military smallpox vaccination program, December 2002 to December 2004. J. Am. Acad. Dermatol.55, 23–31 (2006).
  • Tasker SA, Schnepf GA, Lim M et al. Unintended smallpox vaccination of HIV-1-infected individuals in the United States military. Clin. Infect. Dis.38, 1320–1322 (2004).
  • Casey CG, Iskander JK, Roper MH et al. Adverse events associated with smallpox vaccination in the United States, January–October 2003. JAMA294, 2734–2743 (2005).
  • Poland GA, Grabenstein JD, Neff JM. The US smallpox vaccination program: a review of a large modern erasmallpox vaccination implementationprogram. Vaccine23, 2078–2081 (2005).
  • McMahon AW, Zinderman C, Ball R et al. Comparison of military and civilian reporting rates for smallpox vaccine adverse events. Pharmacoepidemiol. Drug Saf.16(6), 597–604 (2007).
  • Karjalainen J, Heikkila J, Nieminen MD et al. Etiology of mild acute infectious myocarditis. Relation to clinical features. Acta Med. Scand.213, 65–73 (1983).
  • MacAdam D, Whitaker W. Cardiac complications after vaccination for smallpox. Br. Heart J.2, 1099–1100 (1962).
  • Ahlborg B, Linroth K, Nordgren B. ECG-changes without subjective symptoms after smallpox vaccination of military personnel. Acta Med. Scand.464(Suppl.), 127–134 (1966).
  • Helle EP, Koskenvuo K, Heikkila J et al. Myocardial complications of immunizations. Ann. Clin. Res.10, 280–287 (1978).
  • Thorpe LE, Mostashari F, Karpati AM et al. Mass smallpox vaccination and cardiac deaths, New York City, 1947. Emerg. Infect. Dis.10, 917–920 (2004).
  • Swerdlow DL, Roger MH, Morgan J et al. Ischemic cardiac events during the Department of Health and Human Services Smallpox Vaccination Program, 2003. Clin. Infect. Dis.46(Suppl. 3), 234–241 (2008).
  • Eckart RE, Shry EA, Atwood JE et al. Smallpox vaccination and ischemic coronary events in healthy adults. Vaccine25, 8359–8364 (2007).
  • Halsell JS, Riddle JR, Atwood JE et al. Myopericarditis following smallpox vaccination among vaccinia – naive US military personnel. JAMA289, 3283–3289 (2003).
  • von Sonnenburg F, Perona P, Schunk M et al. First clinical experience with a third generation smallpox vaccine in subjects with atopic dermatitis. Presented at: 2006 ASM Biodefense Research Meeting for the American Society for Microbiology. Washington, DC, USA, 15–18 February 2006.
  • Artenstein AW. Bioterrorism and biodefense. In: Infectious Diseases (2nd Edition). Cohen J, Powderly WG (Eds). Mosby, London, UK 99–107 (2003).
  • Ropeik D, Gray G. Risk. Houghton Mifflin Company, MA, USA (2002).
  • Breman JD, Henderson DA. Poxvirus dilemmas – monkeypox, smallpox, and biologic terrorism. N. Engl. J. Med.339(8), 556–559 (1998).
  • Martin TM, Artenstein AW. Bioterrorism. In: The Social Ecology of Infectious Diseases. Mayer KH, Pizer HF (Eds). Academic Press, MA, USA 316–350 (2007).
  • Mack T. A different view of smallpox and vaccination. N. Engl. J. Med.348(5), 460–463 (2003).
  • Reed KD, Melski JW, Graham MB et al. The detection of monkeypox in humans in the western hemisphere. N. Engl. J. Med.350(4), 342–350 (2004).
  • Hammarlund EM, Lewis MW, Carter SV et al. Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. Nat. Med.11(9), 1005–1011 (2005).
  • Bieber T. Atopic dermatitis. N. Engl. J. Med.358(14), 1483–1494 (2008).
  • Ferguson NM, Keeling MJ, Edmunds WJ et al. Planning for smallpox outbreaks. Nature425, 681–685 (2003).
  • Arita I. Smallpox vaccine and its stockpile in 2005. Lancet Infect. Dis.5, 647–651 (2005).
  • Naleway AL, Belogia ES, Greenlee RT, Kieke BA, Chen RT, Shay DK. Eczematous skin disease and recall of past diagnoses: implications for smallpox vaccination. Ann. Intern. Med.139(1), 1–7 (2003).
  • Belongia EA, Naleway A, Kieke B, et al. Validation of a screening instrument to identify persons for exclusion from smallpox vaccination. Clin. Infect. Dis.40, 620–623 (2005).
  • Chapman LE, Iskander JK, Chen RT et al. A process for sentinel case review to assess causal relationships between smallpox vaccination and adverse outcomes, 2003–2004. Clin. Infect. Dis.46(Suppl. 3), 271–293 (2008).
  • Morgan J, Roper MH, Sperling L et al. Myocarditis, pericarditis, and dilated cardiomyopathy after smallpox vaccination among civilians in the United States, January–October 2003. Clin. Infect. Dis.46(Suppl. 3), 242–250 (2008).
  • Institute of Medicine. The Smallpox Vaccination Program: Public Health in an Age of Terrorism. National Academies Press, Washington, DC, USA (2005).
  • Bozzette SA, Boer R, Bhatnagar et al. A model for smallpox-vaccination policy. N. Engl. J. Med.348(5), 416–425 (2003).
  • Wortley PM, Schwartz B, Levy PS, Quick LM, Evans B, Burke B. Healthcare workers who elected not to receive smallpox vaccination. Am. J. Prev. Med.30(3), 258–265 (2006).
  • Kwon N, Raven MC, Chiang WK et al. Emergency physicians’ perspectives on smallpox vaccination. Acad. Emerg. Med.10(6), 599–605 (2003).
  • Wortley PM, Levy PS, Quick L et al. Predictors of smallpox vaccination among healthcare workers and other first responders. Am. J. Prev. Med.32(6), 538–541 (2007).
  • Millock PJ. Legal implications of the smallpox vaccination program. J. Public Health Manag. Pract.9(5), 411–417 (2003).
  • Neff J, Modlin J, Birkhead GS et al. Monitoring the safety of a smallpox vaccination program in the United States: Report of the Joint Smallpox Vaccine Safety Working Group of the Advisory Committee on Immunization Practices and the Armed Forces Epidemiological Board. Clin. Infect. Dis.46, S258–S270 (2008).
  • Wehrle PF, Posch J, Richter KH et al. An outbreak of smallpox in a German hospital and its significance with respect to other recent outbreaks in Europe. Bull. World Health Organ.43, 669–679 (1970).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.